QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
Positive News SentimentPositive News
NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Forecast, Price & News

$1.10
+0.04 (+3.77%)
(As of 09/27/2023 ET)
Compare
Today's Range
$1.06
▼
$1.11
50-Day Range
$1.03
▼
$1.87
52-Week Range
$0.65
▼
$2.58
Volume
799,060 shs
Average Volume
2.36 million shs
Market Capitalization
$180.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

X4 Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
218.2% Upside
$3.50 Price Target
Short Interest
Bearish
6.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$147,030 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.78) to ($0.55) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

259th out of 976 stocks

Biological Products, Except Diagnostic Industry

39th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

XFOR stock logo

About X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

XFOR Price History

XFOR Stock News Headlines

September 19, 2023 | finance.yahoo.com
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
September 8, 2023 | markets.businessinsider.com
X4 Pharmaceuticals (XFOR) Receives a Buy from B.Riley Financial
September 27, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
September 6, 2023 | finance.yahoo.com
X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 5, 2023 | msn.com
X4 submits New Drug Application to FDA for WHIM syndrome drug
September 5, 2023 | finance.yahoo.com
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
August 24, 2023 | msn.com
X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market
August 15, 2023 | finance.yahoo.com
XFOR: NDA for Mavorixafor in WHIM Syndrome in Early 2H23…
September 27, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
August 10, 2023 | msn.com
X4 Pharmaceuticals GAAP EPS of -$0.33 misses by $0.16
August 10, 2023 | finance.yahoo.com
X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
August 8, 2023 | finance.yahoo.com
X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer
August 3, 2023 | finance.yahoo.com
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
August 2, 2023 | finance.yahoo.com
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
July 22, 2023 | theglobeandmail.com
Instrument Name X4 Pharmaceuticals Inc Instrument Symbol (XFOR-Q)
June 14, 2023 | msn.com
XFOR: Initiating Coverage of X4 Pharmaceuticals; Investing on More Than Just a WHIM…
June 14, 2023 | finance.yahoo.com
XFOR: Initiating Coverage of X4 Pharmaceuticals; Investing on More Than Just a WHIM…
June 13, 2023 | finance.yahoo.com
X4 Pharmaceuticals Expected to Join Russell 3000® Index
May 25, 2023 | markets.businessinsider.com
Stifel Nicolaus Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)
May 17, 2023 | msn.com
Stifel Maintains X4 Pharmaceuticals (XFOR) Buy Recommendation
May 17, 2023 | msn.com
Unusual Call Option Trade in X4 Pharmaceuticals (XFOR) Worth $24.36K
May 17, 2023 | msn.com
X4 Pharma Highlights 'Significant Reduction' Rate In Severity, Duration Of Infections
May 16, 2023 | finance.yahoo.com
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
May 16, 2023 | finance.yahoo.com
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
May 5, 2023 | markets.businessinsider.com
What 5 Analyst Ratings Have To Say About X4 Pharmaceuticals
May 5, 2023 | msn.com
HC Wainwright & Co. Reiterates X4 Pharmaceuticals (XFOR) Buy Recommendation
May 4, 2023 | msn.com
X4 Pharmaceuticals: Q1 Earnings Insights
See More Headlines
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XFOR
CUSIP
N/A
CIK
1501697
Web
www.x4pharma.com
Phone
(857) 529-8300
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+218.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-93,870,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-204.49%
Return on Assets
-92.04%

Debt

Debt-to-Equity Ratio
0.47
Current Ratio
6.64
Quick Ratio
6.64

Sales & Book Value

Annual Sales
$3 million
Price / Sales
60.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
1.80

Miscellaneous

Outstanding Shares
164,430,000
Free Float
162,649,000
Market Cap
$180.87 million
Optionable
Not Optionable
Beta
0.74
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Paula Ragan Ph.D. (Age 53)
    CEO, Pres & Director
    Comp: $963.58k
  • Mr. Adam S. MostafaMr. Adam S. Mostafa (Age 43)
    CFO, Treasurer & Corp. Sec.
    Comp: $699.18k
  • Dr. Mary DiBiase Ph.D. (Age 62)
    Chief Operating Officer
    Comp: $661.59k
  • Dr. Richard Peters M.D. (Age 60)
    Ph.D., Founder
  • Dr. Renato T. Skerlj Ph.D.
    Founder
  • Dr. Keith T. Flaherty M.D. (Age 52)
    Founder & Member of Corp. Advisory Board
  • Dr. Arthur Taveras Ph.D. (Age 59)
    Chief Scientific Officer
  • Dr. Glenn Schulman M.P.H.
    Pharm. D., Pharm.D., VP of Investor Relations & Corp. Communications
  • Dr. Robert David Arbeit (Age 75)
    Sr. VP of Clinical Devel. and Translational Research
  • Mr. Mark Baldry M.B.A. (Age 59)
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













XFOR Stock - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XFOR shares.
View XFOR analyst ratings or view top-rated stocks.

What is X4 Pharmaceuticals' stock price forecast for 2023?

5 Wall Street analysts have issued 12 month price objectives for X4 Pharmaceuticals' shares. Their XFOR share price forecasts range from $3.00 to $5.00. On average, they predict the company's share price to reach $3.50 in the next year. This suggests a possible upside of 218.2% from the stock's current price.
View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts.

How have XFOR shares performed in 2023?

X4 Pharmaceuticals' stock was trading at $0.9930 on January 1st, 2023. Since then, XFOR stock has increased by 10.8% and is now trading at $1.10.
View the best growth stocks for 2023 here.

When is X4 Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our XFOR earnings forecast.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.16. During the same quarter in the previous year, the firm posted ($0.60) EPS.

What ETF holds X4 Pharmaceuticals' stock ?

Simplify Propel Opportunities ETF holds 400,000 shares of XFOR stock, representing 0.72% of its portfolio.

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (13.06%), BlackRock Inc. (7.44%), Polar Capital Holdings Plc (4.09%), Stonepine Capital Management LLC (3.77%), Perceptive Advisors LLC (2.16%) and Geode Capital Management LLC (1.92%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Arthur Taveras, Derek M Meisner, Derek M Meisner, Mary Dibiase, Michael S Wyzga, Murray Stewart and Paula Ragan.
View institutional ownership trends.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $1.10.

How much money does X4 Pharmaceuticals make?

X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $180.87 million and generates $3 million in revenue each year. The company earns $-93,870,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com.

This page (NASDAQ:XFOR) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -